This announcement is a separate document:
康方生物-B：與正大天晴進行有關派安普利（PD-1單抗(AK105)）治療肝細胞癌的III期註冊試驗的持續關連交易物料及服務總採購協議
AKESO, INC. - B: CONTINUING CONNECTED TRANSACTIONS WITH CHIA TAI TIANQING IN RELATION TO PHASE III REGISTRATION TRIAL OF PENPULIMAB (PD-1 MONOCLONAL ANTIBODY, AK105) FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA MASTER MATERIALS AND SERVICES PROCUREMENT AG
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.